Optomeditech raises $2.5m from Lifeline and Sitra

Optomeditech CEO Ami Rubinstein told unquote" the new capital would be used to generate more clinical evidence on the benefits of the company's products as well as clinical trials between now and next summer.

The company is preparing for its commercial launch in Europe in the second half of 2015 – the new funding will help ramp up production in anticipation of this.

Sitra will join Lifeline on the board of directors following the investment round.

Previous funding
External funding was first raised by the company in early 2012, in what Rubinstein called a "family and friends" round.

The second round was an investment from Lifeline in November of the same year, which saw the VC's founding partner Time Ahopelto become chairman of Optomeditech's board.

Company
Founded in 2011 and based in Espoo, Optomeditech develops and markets intravenous catheter and blood collection needle products.

The company is currently in the process of securing US Federal Drug Administration approval for its first intravenous catheter product, OptiVein, which it expects to have on the market in 2015.

Optomeditech has four full-time employees.

People
Lifeline Ventures founding partner Timo Ahopelto worked on the deal for the VC. Ami Rubinstein is the CEO of Optomeditech.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Nordics
• Early-stage
• Healthcare
• Finland